Newly-Created Executive Role to Support Company’s Planned Expansion of U.S. Operations
MADRID and NEW YORK, November 16, 2016 /PRNewswire/ --
PharmaMar (MCE:PHM), a biotechnology company developing marine-derived oncology drugs, today announced that Pascal Besman has joined the company in the newly-created role of Chief Operating Officer, effective immediately. Mr. Besman will be based in New York and will oversee the implementation of PharmaMar’s operational infrastructure in the United States. Mr. Besman joins PharmaMar from Maxim Group, a New York-based global investment bank, where he served as Head of Healthcare Equity Sales since 2014.
“With Yondelis on the market in the US and our key pipeline program PM1183 in several pivotal Phase 3 studies, now is the ideal time to welcome Pascal to our team as we further expand our presence in the U.S.,” said José María Fernández Sousa-Faro, Ph.D., President, Chief Executive Officer and Chairman of the Board of PharmaMar. “As a global, revenue-generating oncology company, we look forward to leveraging Pascal’s expertise in the biotechnology sector and U.S. capital markets as we continue to expand our efforts in the US.”
“I have been impressed with PharmaMar’s progress to date, and I am honored to join the team at this exciting time as it seeks to build out its U.S. infrastructure and continues to execute against its business objectives and clinical development timelines,” said Mr. Besman. “PharmaMar has a proven disruptive approach to help cancer patients and I look forward to contributing to the Company’s future success as we seek to continue building shareholder value.”
In addition to Maxim Group, Mr. Besman served as a healthcare specialist and institutional equity salesperson at several investment banks, including JMP Securities, UBS, Bear Stearns, Lehman Brothers and Merrill Lynch. He authored a widely-read weekly biotech overview newsletter for C-suite executives entitled The Buzz. Mr. Besman holds a B.Sc. from the London School of Economics.
Paula Fernández, Media Relations Manager, +34-638-79-62-15
Investor Relations, +34-914444500
